Replimune REPL
NASDAQ REPL
$23.07 -0.21 (-0.90%)
As of: Nov 11, 2026 · 9:43 AM EST

Replimune (REPL) Return on Capital Employed [ROCE] (2018 - 2026)

Updated

Replimune's Return on Capital Employed [ROCE] was -100.78% in fiscal Q2 2027 (quarter ended Sep 30, 2026), down 15.79 percentage points from -84.99% a year earlier but up 16.44 percentage points from the prior quarter.

Analysis

Replimune (REPL) Return on Capital Employed [ROCE] (2018 - 2026) Analysis & Trends

For FY2026 (ended Mar 31, 2026), Return on Capital Employed [ROCE] at Replimune came in at -83.39%, down 26.16 percentage points from FY2025.

  • Return on Capital Employed [ROCE] has now declined for five consecutive fiscal years, with a five-year change of -62.02 percentage points (FY2021 to FY2026).
  • In earlier fiscal years, Return on Capital Employed [ROCE] was -57.23% in FY2025 (-12.66 pp), -44.57% in FY2024 (-10.52 pp), -34.05% in FY2023 (-9.47 pp) and -24.58% in FY2022 (-3.20 pp).
  • Quarterly Return on Capital Employed [ROCE] has moved between -117.22% (fiscal Q1 2027) and -22.79% (fiscal Q3 2022) over five years.
  • Compared with a year earlier, Return on Capital Employed [ROCE] has declined for 20 straight quarters, with an average year-over-year change of -30.68 percentage points over the last eight quarters.
  • Across the past five years, year-over-year drop in Return on Capital Employed [ROCE] ran from 0.83 percentage points in fiscal Q4 2025 to 65.64 percentage points in fiscal Q4 2026.
  • Per Business Quant data, REPL's Return on Capital Employed [ROCE] in the three fiscal quarters before Q2 2027 was -117.22% (Q1 2027), -116.44% (Q4 2026) and -104.65% (Q3 2026).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROCE (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 35.41%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 17.52%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 21.60%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 4.65%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 9.91%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 17.37%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -6.15%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 11.32%
10 Replimune 2.21 Bn 1.17 Bn - -100.78%
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 -100.78%
Jun 30, 2026 -117.22%
Mar 31, 2026 -116.44%
Dec 31, 2025 -104.65%
Sep 30, 2025 -84.99%
Jun 30, 2025 -65.36%
Mar 31, 2025 -50.79%
Dec 31, 2024 -47.92%
Sep 30, 2024 -48.98%
Jun 30, 2024 -49.72%
Mar 31, 2024 -49.96%
Dec 31, 2023 -44.99%
Sep 30, 2023 -39.41%
Jun 30, 2023 -32.35%
Mar 31, 2023 -28.16%
Dec 31, 2022 -29.40%
Sep 30, 2022 -33.98%
Jun 30, 2022 -29.96%
Mar 31, 2022 -26.15%
Dec 31, 2021 -22.79%
API Access

Replimune Return on Capital Employed [ROCE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-capital-employed-%5Broce%5D&ticker=REPL&period=max&api_key=YOUR_API_KEY